CN1160369C - 抗细胞质胸苷激酶-IgY抗体的制备及肿瘤诊断组合物 - Google Patents
抗细胞质胸苷激酶-IgY抗体的制备及肿瘤诊断组合物 Download PDFInfo
- Publication number
- CN1160369C CN1160369C CNB021347271A CN02134727A CN1160369C CN 1160369 C CN1160369 C CN 1160369C CN B021347271 A CNB021347271 A CN B021347271A CN 02134727 A CN02134727 A CN 02134727A CN 1160369 C CN1160369 C CN 1160369C
- Authority
- CN
- China
- Prior art keywords
- antibody
- igy
- thymidine kinase
- cell
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 46
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 title claims abstract description 39
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 title claims abstract description 19
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229940104230 thymidine Drugs 0.000 title claims abstract description 19
- 230000001086 cytosolic effect Effects 0.000 title claims abstract description 12
- 238000003745 diagnosis Methods 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 208000019065 cervical carcinoma Diseases 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 38
- 150000001413 amino acids Chemical group 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 238000001378 electrochemiluminescence detection Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 210000002969 egg yolk Anatomy 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 6
- 238000012151 immunohistochemical method Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000007413 biotinylation Methods 0.000 claims description 5
- 230000006287 biotinylation Effects 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 102000003992 Peroxidases Human genes 0.000 claims description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 238000003809 water extraction Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 12
- 238000012544 monitoring process Methods 0.000 abstract description 4
- 238000003556 assay Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002055 immunohistochemical effect Effects 0.000 abstract 1
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 description 38
- 201000011510 cancer Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 14
- 238000013016 damping Methods 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000005406 washing Methods 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000013399 early diagnosis Methods 0.000 description 6
- 230000022983 regulation of cell cycle Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229920001206 natural gum Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 101710083889 Alpha-fetoprotein Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000000516 activation analysis Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- -1 sulfuric acid amine Chemical class 0.000 description 2
- 108010036901 thymidine kinase 1 Proteins 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021347271A CN1160369C (zh) | 2002-09-13 | 2002-09-13 | 抗细胞质胸苷激酶-IgY抗体的制备及肿瘤诊断组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021347271A CN1160369C (zh) | 2002-09-13 | 2002-09-13 | 抗细胞质胸苷激酶-IgY抗体的制备及肿瘤诊断组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1414017A CN1414017A (zh) | 2003-04-30 |
CN1160369C true CN1160369C (zh) | 2004-08-04 |
Family
ID=4747865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021347271A Expired - Lifetime CN1160369C (zh) | 2002-09-13 | 2002-09-13 | 抗细胞质胸苷激酶-IgY抗体的制备及肿瘤诊断组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1160369C (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101231288B (zh) * | 2008-01-31 | 2011-08-10 | 丁克祥 | 一种基于磁性纳米微粒的人胸苷激酶荧光免疫分析新方法 |
CN101275954B (zh) * | 2008-05-09 | 2012-01-04 | 丁克祥 | 一种简便快速测定人类i型胸苷激酶基因蛋白的乳癌预警芯片 |
CN102516390B (zh) * | 2011-10-28 | 2013-10-30 | 周际 | 一种多表位tk1抗体的制备及其在评估肿瘤患者治疗效果中的应用 |
CN102432683B (zh) * | 2011-10-28 | 2013-10-30 | 周际 | 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 |
CN102504027B (zh) * | 2011-10-28 | 2013-10-30 | 周际 | 一种多表位tk1抗体的制备及其在人群体检筛查中早期肿瘤检测和风险预警中的应用 |
EP3083698B1 (en) * | 2013-12-19 | 2019-04-10 | Arocell AB | Monoclonal anti-tk1 antibodies |
CN104672331B (zh) * | 2014-10-14 | 2018-10-09 | 华瑞同康生物技术(深圳)有限公司 | 一种抗胸苷激酶1抗体的制备方法及其在解脲支原体菌增殖中的应用 |
CN105675880B (zh) * | 2016-01-20 | 2018-11-27 | 华南师范大学 | 快速检测低丰度蛋白质的无封闭的蛋白质印迹法 |
CN105906711B (zh) * | 2016-05-03 | 2019-09-27 | 中农威特生物科技股份有限公司 | 一种抗o型和a型口蹄疫病毒卵黄抗体的制备方法、产品及其用途 |
CN107365386A (zh) * | 2016-05-12 | 2017-11-21 | 杨国民 | 一种抗细胞质胸苷激酶-IgG抗体的制备方法和用途 |
CN108061795B (zh) * | 2017-11-24 | 2020-02-18 | 大连医科大学 | 提高检测灵敏度的蛋白质免疫印迹法 |
CN110872354B (zh) * | 2018-09-04 | 2022-11-01 | 华瑞同康生物技术(深圳)有限公司 | 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 |
CN110873711B (zh) * | 2018-09-04 | 2022-02-22 | 华瑞同康生物技术(深圳)有限公司 | 一种基于全自动化学发光分析仪的血清tk1检测试剂盒 |
CN113150159A (zh) * | 2021-02-20 | 2021-07-23 | 华瑞同康生物技术(深圳)有限公司 | 鸡抗人胸苷激酶1-IgY多克隆抗体用于识别大分子复合物的用途 |
-
2002
- 2002-09-13 CN CNB021347271A patent/CN1160369C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1414017A (zh) | 2003-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1160369C (zh) | 抗细胞质胸苷激酶-IgY抗体的制备及肿瘤诊断组合物 | |
JPH08275778A (ja) | モノクローナル抗体生産性ハイブリドマ細胞系 | |
CA2280930A1 (en) | Protein markers for lung cancer and use thereof | |
ACTON et al. | Variations among sublines of inbred AKR mice | |
CN1761682A (zh) | 单克隆抗体与产生该单克隆抗体的杂交瘤 | |
CN1541222A (zh) | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 | |
CN103278627A (zh) | 一种检测非洲猪瘟病毒抗体的多抗原elisa试剂盒 | |
CN104471404A (zh) | 癌的检测方法 | |
CN101949937A (zh) | 卵巢癌肿瘤标志物he4时间分辨荧光免疫检测试剂盒 | |
CN101960309A (zh) | 用于肾癌诊断或检测的组合物及方法 | |
CN108795880B (zh) | 产生人胸苷激酶1(tk1)特异性单克隆抗体的小鼠杂交瘤细胞株及其应用 | |
Nishioka et al. | Localization of α-fetoprotein in hepatoma tissues by immunofluorescence | |
CN102782500B (zh) | 胃癌检测用的标志物和胃癌检测方法 | |
CN102103144A (zh) | 检测卵巢癌肿瘤标志物he4蛋白的方法 | |
CN102516390A (zh) | 一种多表位tk1抗体的制备及其在评估肿瘤患者治疗效果中的应用 | |
CN1718588A (zh) | 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断方法、诊断试剂盒及其应用 | |
CN102608332A (zh) | 一种草鱼白细胞介素10酶联免疫检测方法 | |
CN1060310A (zh) | 用于免疫诊断结核病的新的17KDa蛋白抗原及由其衍生的肽片段的制备方法 | |
Shively et al. | Amino-terminal sequence of a carcinoembryonic antigen-like glycoprotein isolated from the colonic lavages of healthy individuals | |
CN107266567A (zh) | Lcrmp4单克隆抗体及其制备方法与应用 | |
CN103848916A (zh) | 一种抗cp4 epsps单克隆抗体的制备方法、编码序列及其应用 | |
CN1058099A (zh) | 一种体外检测人和动物中存在环状颗粒和恶性肿瘤的方法及探针 | |
CN1017349B (zh) | 抗人心房钠尿肽的单克隆抗体 | |
CN110275014B (zh) | 一种术中快速鉴别甲状腺乳头状癌颈淋巴结转移的方法 | |
CN105622751B (zh) | 抗Ki67蛋白单克隆抗体及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: HUARUI TONGKANG BIOTECHNOLOGY ( SHENZHEN ) CO., LT Free format text: FORMER NAME OR ADDRESS: HUARUITONGKANG BIOLOGY TECHNOLOGY CO., LTD., SHENZHEN CITY |
|
CP03 | Change of name, title or address |
Address after: 2-304A.B, a biological incubator building in Nanshan District hi tech Development Zone, Shenzhen Patentee after: SHENZHEN SINO-SWED TONGKANG BIO-TECH Ltd. Address before: Room 2-304, a bio incubator building, high tech Zone, Shenzhen, Guangdong Patentee before: SHENZHEN HUARUI TONGKANG BIOTE |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Ji Document name: Notification of Passing Examination on Formalities |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Ji Document name: Resume right request approval decision |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of anti cytoplasmic thymidine kinase-IgY and tumor diagnosis composition Effective date of registration: 20110808 Granted publication date: 20040804 Pledgee: Shanghai Puhua Kant Biological Technology Co.,Ltd. Pledgor: SHENZHEN SINO-SWED TONGKANG BIO-TECH Ltd. Registration number: 2011990000301 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150626 Granted publication date: 20040804 Pledgee: Shanghai Puhua Kant Biological Technology Co.,Ltd. Pledgor: SHENZHEN SINO-SWED TONGKANG BIO-TECH Ltd. Registration number: 2011990000301 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
DD01 | Delivery of document by public notice |
Addressee: SHENZHEN SINO-SWED TONGKANG BIO-TECH Ltd. Document name: Notification to Pay the Fees |
|
CP02 | Change in the address of a patent holder |
Address after: 518000 Guangzhou Longhua District Guanlan Street Xinlan Community Tourist Road 1301-76 Yinxing Zhijie Phase II Building A201A301 Patentee after: SHENZHEN SINO-SWED TONGKANG BIO-TECH Ltd. Address before: 518057 Biological Incubator Building, Nanshan High-tech Middle School, Shenzhen, 2-304A.B. Patentee before: SHENZHEN SINO-SWED TONGKANG BIO-TECH Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20040804 |